Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Packaging: Is Non-Inferiority Enough For A New Claim?

Executive Summary

Industry exec suggests new packages need be merely no worse than the classic amber vial to gain a claim, but US FDA says packaging intended to fight abuse should be better.

Advertisement

Related Content

Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
Gottlieb Worries Vaccine Policy Could Spark Federalism Debate
Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says
Opioid Approvals: Congress Wants US FDA Guidance On Abuse Potential
Opioid Bills Could Enhance US FDA Approval, Withdrawal Authority
Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities
Gottlieb: Hurricane Maria May Cause Critical Drug Shortages By Q1 2018
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel